Disability profile of MS did not change over 10 years in a population-based prevalence cohort.
about
Prevalence of multiple sclerosis symptoms across lifespan: data from the NARCOMS Registry.Idiopathic inflammatory-demyelinating diseases of the central nervous system.Hyperbaric oxygen therapy for multiple sclerosis.A primary care-based needs assessment of people with multiple sclerosis.Benign multiple sclerosis: does it exist?Six-minute walk test for persons with mild or moderate disability from multiple sclerosis: performance and explanatory factorsPrevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: a cross-sectional survey.Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating diseaseStatin therapy and multiple sclerosis disability in a population-based cohort.African ancestry is a predictor factor to secondary progression in clinical course of multiple sclerosis.Disability evolution in multiple sclerosis: how to deal with missing transition times in the Markov model?Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review.Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.Hospitalization rates and discharge status in multiple sclerosisMultiple sclerosis registry in Germany: results of the extension phase 2005/2006Depression levels and interferon treatment in people with multiple sclerosis.Clinical prognostic factors in multiple sclerosis: a natural history review.A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease.Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium.Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study.Clinical course of multiple sclerosis: A nationwide cohort study.Voxelwise analysis of conventional magnetic resonance imaging to predict future disability in early relapsing-remitting multiple sclerosis.A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.The relationship between subjective reports of fatigue and executive control in multiple sclerosisLong-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis.Defining the natural history of MS: the need for complete data and rigorous definitions.Obstetrical epidural and spinal anesthesia in multiple sclerosis.SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis.Harnessing electronic medical records to advance research on multiple sclerosis.Disability weight for each level of the Expanded Disability Status Scale in multiple sclerosis.[MS registry in Germany--design and first results of the pilot phase].Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression.Increasing incidence of multiple sclerosis among women in Lorraine, Eastern France.Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment.Total knee arthroplasty in multiple sclerosis.Meta-analysis of prevalence
P2860
Q31028561-E8D78208-2D17-4BB3-88C2-57BCE5580ABAQ31103990-056D66CD-865F-4001-B826-62C3B17BC083Q34111845-602438C0-D274-4B5C-8306-599F5DC9DAFBQ34620392-328719C9-3E0F-4B55-A10F-5C388D5CC406Q34640135-3297ADBC-4A02-4ECC-B317-B2BF00CA8FDAQ34795164-17683A25-FCC1-4B09-BF19-3634B56A8AF3Q34903545-D0E2F80E-F6FD-4C45-9C8E-2A78AE9A3ADCQ35485603-5CB63E88-CB52-454F-83D2-473C909BF30BQ35612796-79A4A9C2-DF18-4298-863A-D2B07A59D0D0Q36440208-31E24B5A-C069-4B62-97D7-772E562F9F1DQ36704225-9FE766B0-E99F-4A05-BA5D-F47B6E90CD6FQ36722180-84B40F00-4CFA-4A28-B99F-148E7587F790Q36839629-1BD62110-6AB6-421D-8F54-C0919E964196Q36882707-FCB06221-C925-4C07-A320-47DEFE6FE811Q37228391-D86EC8FD-BAA4-4F4F-BFF4-F68356E8A890Q37442193-DAB683ED-C8E4-4FAB-93D0-6211268CBE00Q37642594-92435B8E-2C48-4733-ABD2-5484ECE466FAQ38290281-6D72CD2A-E45A-4352-9313-58FF2E43F5A1Q38440655-5EBC8B8A-5EFD-4DCB-87DC-BFAFEF239F14Q38677868-E6CC61C8-B63E-4ECD-91BD-46690D610D0FQ38881956-15AE6D77-70F7-40CC-A155-2CC7C082C2EEQ39107261-BAA944DF-D475-4D80-B381-73E38C5217D3Q39635811-68DF9371-1FD6-47BA-8B7B-9332C293ECA8Q41369774-09D9875D-9177-4BA0-8F1A-073BE760A1F6Q41681605-BDE4EA51-6A90-4B7F-84F8-ABAE3243DB78Q41909448-ED34D396-A53A-464E-962F-D8330D9D94F3Q42643054-6583C293-4ECB-4EB0-B454-CC3CDFF909DFQ43459294-206FF38F-3F3F-462A-8721-7D54429CB406Q44311224-8395BF07-5EA6-4458-9E92-DB2F326B750DQ46861116-957431F8-A713-415A-878B-87EA3AD633E5Q46870849-9ADCA418-4A3C-4496-A7EC-D9A9799FD05AQ47178380-18CD9296-0DEB-4456-80CB-E8AB19711A4DQ47190259-A4D1ED09-EF9B-463D-9576-3D355A813932Q50231895-C9950E92-BCE1-40A9-9F0D-834A50E88719Q50561840-B2940519-13DB-4BA6-B931-D02290BDB5DEQ51103478-98DF344A-902C-4E48-A804-516258E1747BQ52854537-1BBF0174-C82D-48CE-B555-D7FEA38B0575Q54111268-2E230A48-1897-405F-82EF-4F3BFA405C7FQ57243585-F42B02AB-8D9A-47DC-B8F8-2DA4C0E23877
P2860
Disability profile of MS did not change over 10 years in a population-based prevalence cohort.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Disability profile of MS did n ...... ation-based prevalence cohort.
@ast
Disability profile of MS did n ...... ation-based prevalence cohort.
@en
type
label
Disability profile of MS did n ...... ation-based prevalence cohort.
@ast
Disability profile of MS did n ...... ation-based prevalence cohort.
@en
prefLabel
Disability profile of MS did n ...... ation-based prevalence cohort.
@ast
Disability profile of MS did n ...... ation-based prevalence cohort.
@en
P2093
P356
P1433
P1476
Disability profile of MS did n ...... ation-based prevalence cohort.
@en
P2093
Jorgensen NW
McClelland RL
Noseworthy JH
Pittock SJ
Rodriguez M
Weigand SD
P304
P356
10.1212/WNL.62.4.601
P407
P577
2004-02-01T00:00:00Z